9 Meters Biopharma Inc at BMO Biopharma Spotlight Series: Innovation in GI (Virtual) Transcript
Hi, everyone. I'm Gary Nachman, the biopharma analyst at BMO. And we're very excited to have the management team from 9 Meters with us, John Temperato, President and CEO; and Patrick Griffin, who is dialed in, Chief Medical Officer. 9 Meters has a very robust pipeline in GI, targeting rare diseases like short bowel syndrome, but also much larger markets like celiac disease. So really thrilled to have both of you here to discuss some of the exciting programs that you're working on.
Thanks, Gary. We're happy to be here.
Questions & Answers
Great to have you. Okay. So we only have 20 minutes, a lot to cover. So start with short bowl syndrome, which we'll be calling SBS. So the current unmet needs for those patients and how your lead product, vurolenatide, could potentially provide a substantial benefit for these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
